Chemours Co
Financial highlights
| Metric | FY December 31, 2025 | FY September 30, 2025 | FY June 30, 2025 | FY March 31, 2025 | FY December 31, 2024 |
|---|---|---|---|---|---|
| Revenue | $5.8B | — | — | — | $5.8B |
| Gross profit | $902.0M | — | — | — | $1.1B |
| Operating expenses | $966.0M | — | — | — | $823.0M |
| Cost of revenue | $4.9B | — | — | — | $4.6B |
| Cash from operations | $264.0M | — | — | — | -$633.0M |
| Capital expenditure | $213.0M | — | — | — | $360.0M |
| Free cash flow | $51.0M | — | — | — | -$993.0M |
| Impairments | $24.0M | — | — | — | $27.0M |
| Total assets | $7.4B | $7.5B | $7.5B | $7.4B | $7.5B |
| Total liabilities | $7.1B | — | $7.2B | $6.8B | $6.9B |
Shares outstanding 150.4M · Free float 98.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.